Ryan Engel
Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Ryan Engel

Hematology | Oncology
1221 N Highland Ave 1st Fl, 
Aurora, IL 
On Staff At
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
1221 N Highland Ave 1st Fl, 
Aurora, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ryan Engel is a Hematologist and an Oncologist in Aurora, Illinois. Dr. Engel is rated as an Experienced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Inflammatory Breast Cancer, and Paget Disease of the Breast.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Residency
Advocate Lutheran General Hospital, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in WI
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
McGaw Medical Center of Northwestern University, Hematology/Oncology
Hospital Affiliations
Advocate Christ Hospital & Medical Center
Advocate Good Samaritan Hospital
Javon Bea Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Advocate Infusion Center
1221 N Highland Ave 1st Fl, Aurora, IL 60506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3

1 Total Publications

Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: May 04, 2019
Similar Doctors
Devalingam Mahalingam
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Devalingam Mahalingam
Hematology | Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Devalingam Mahalingam
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (37.6 miles away)
866-587-4322
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Devalingam Mahalingam is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mahalingam has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Liver Embolization.

Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Aparna Kalyan
Hematology | Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Aparna Kalyan
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (37.6 miles away)
866-587-4322
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aparna Kalyan is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Kalyan has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Tissue Biopsy, and Liver Embolization.

Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Daniel V. Catenacci
Hematology | Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Daniel V. Catenacci
Hematology | Oncology
5841 S Maryland Ave, 
Chicago, IL 
 (37.3 miles away)
888-824-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Catenacci is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Catenacci is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Stomach Cancer, Cholangiocarcinoma (Bile Duct Cancer), Gastroesophageal Junction Cancer, and Colorectal Cancer. Dr. Catenacci is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Engel's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 114 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile